BioRem Inc.
BioRem Inc. (BIRMF) Financial Performance & Income Statement Overview
Review BioRem Inc. (BIRMF) income statement, balance sheet, and cash flow reports with annual and quarterly breakdowns.
BioRem Inc. (BIRMF) Income Statement & Financial Overview
Review BioRem Inc. BIRMF income statement with detailed quarterly and annual figures.
| Metric | Q4 2024 | Q3 2024 | Q2 2024 | Q1 2024 |
|---|---|---|---|---|
| Revenue | $9.32M | $14.89M | $7.30M | $5.92M |
| Cost of Revenue | $7.72M | $9.86M | $5.64M | $4.14M |
| Gross Profit | $1.60M | $5.02M | $1.66M | $1.78M |
| Gross Profit Ratio | $0.17 | $0.34 | $0.23 | $0.30 |
| R&D Expenses | $7138.00 | $7944.00 | $13512.00 | $15265.00 |
| SG&A Expenses | $1.30M | $1.99M | $1.13M | $1.20M |
| Operating Expenses | $1.31M | $1.99M | $1.14M | $1.22M |
| Total Costs & Expenses | $9.03M | $11.86M | $6.79M | $5.36M |
| Interest Income | $0.00 | $0.00 | $0.00 | $0.00 |
| Interest Expense | $46930.00 | $47429.00 | $50117.00 | $50949.00 |
| Depreciation & Amortization | $139966.00 | $184657.00 | $74829.00 | $73674.00 |
| EBITDA | $426542.00 | $3.21M | $587291.00 | $634550.00 |
| EBITDA Ratio | $0.05 | $0.22 | $0.08 | $0.11 |
| Operating Income | $286576.00 | $3.03M | $513070.00 | $560880.00 |
| Operating Income Ratio | $0.03 | $0.20 | $0.07 | $0.09 |
| Other Income/Expenses (Net) | -$46930.00 | -$47429.00 | -$50117.00 | -$95881.00 |
| Income Before Tax | $239646.00 | $2.98M | $462345.00 | $465000.00 |
| Income Before Tax Ratio | $0.03 | $0.20 | $0.06 | $0.08 |
| Income Tax Expense | $68910.00 | $790342.00 | $122521.00 | $120900.00 |
| Net Income | $170736.00 | $2.19M | $339824.00 | $344099.00 |
| Net Income Ratio | $0.02 | $0.15 | $0.05 | $0.06 |
| EPS | $0.01 | $0.14 | $0.02 | $0.02 |
| Diluted EPS | $0.00 | $0.12 | $0.02 | $0.02 |
| Weighted Avg Shares Outstanding | $16.14M | $15.80M | $15.70M | $15.70M |
| Weighted Avg Shares Outstanding (Diluted) | $0.00 | $18.58M | $18.52M | $15.70M |
Financial performance has remained strong, with revenue growing from $5.92M in Q1 2024 to $9.32M in Q4 2024. Gross profit continued to perform well, with margins at 17% in the latest quarter. Operating income reached $286576.00 in Q4 2024, holding a steady 3% margin. While R&D and SG&A expenses fluctuated, EBITDA remained robust at $426542.00. Net income dropped to $170736.00, keeping EPS at $0.01. With disciplined cost control and operational efficiency, the company supported consistent profitability, reflecting its ability to deliver stable shareholder value.
Unlock 25+ Years of Financial Data
Get access to extended historical data, advanced metrics, and more with our premium plan